Fort Collins, Colorado, May 14, 2024 (GLOBE NEWSWIRE) --
Rising incidences of uterine sarcoma in the population drive the need for treatment.
The growth of the uterine sarcoma treatment market is strongly driven by the increasing incidence of uterine sarcoma worldwide. According to the American Cancer Society, approximately 65,950 new cases of uterine cancer are expected to be diagnosed in the United States in 2023, with uterine sarcoma accounting for about 3-5% of these cases. Moreover, the World Health Organization's International Agency for Research on Cancer (IARC) projects that the global incidence of uterine cancer will rise to 1.2 million cases by 2040. The growing prevalence of uterine sarcoma is attributed to factors such as increasing obesity rates, evolving reproductive patterns, and an aging population.
Another significant Uterine Sarcoma Treatment market driver is the rapid advancements in targeted therapies and immunotherapies. These innovative treatment modalities have exhibited promising outcomes in managing various types of uterine sarcoma, including leiomyosarcoma and endometrial stromal sarcoma. For example, in 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dostarlimab, an anti-PD-1 monoclonal antibody, for treating recurrent or advanced endometrial cancer. Additionally, ongoing clinical trials explore the efficacy of diverse targeted therapies, such as tyrosine kinase and mTOR inhibitors, in treating uterine sarcoma, contributing to market growth.
Request Sample Report:
Segmentation Overview:
The uterine sarcoma treatment market has been segmented into type, treatment type, end-user, and region.
Leiomyosarcoma is the largest segment by disease type.
- In 2023, Leiomyosarcoma was the largest segment by disease type. It is the most common type of uterine sarcoma, accounting for approximately 60-70% of all cases.
Surgery is the leading treatment, accounting for a significant market share in 2023.
- Surgery is the largest segment within the uterine sarcoma treatment market by treatment type. Surgery remains the cornerstone of treatment for most types of uterine sarcoma, especially in early-stage disease.
Ask For Discount
Uterine Sarcoma Treatment Market Report Highlights:
- The uterine sarcoma treatment market growth is anticipated at a CAGR of 8.3% by 2032.
- Increasing incidence of uterine sarcoma encourages the treatment needs in the population.
- North America is the largest regional market for Uterine Sarcoma Treatment. The United States, in particular, dominates the North American market due to factors such as high healthcare expenditure, advanced medical infrastructure, and the presence of major pharmaceutical companies.
- Some prominent players in the uterine sarcoma treatment market report include Pfizer Inc., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca PLC, Bayer AG, Amgen Inc., Takeda Pharmaceutical Company Limited, and Gilead Sciences, Inc.
Looking Exclusively For Region/Country Specific Report?
About DataHorizzon Research:
DataHorizzon is a market research and advisory company that assists organizations across the globe in formulating growth strategies for changing business dynamics. Its offerings include consulting services across enterprises and business insights to make actionable decisions. DHR’s comprehensive research methodology for predicting long-term and sustainable trends in the market facilitates complex decisions for organizations.
Contact:
Mail: sales@datahorizzonresearch.com
Ph: +1-970-672-0390
Website: https://datahorizzonresearch.com/
Follow Us: LinkedIn
Recent Publications
Sickle Cell Disease Market 2024 to 2032
Prostate Cancer Therapeutics Market 2024 to 2032
Clinical Trial Imaging Market 2024 to 2032
Mental Health Market 2024 to 2032
Breast Cancer Diagnostics Market 2024 to 2032
